Evaluation of CLP With and Without Spironolactone in Heart Failure Patients With Chronic Kidney Disease
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Heart failure with New York Heart Association (NYHA) Classification II or III
Chronic kidney disease
Cardiac ejection fraction <40%
On heart failure therapy including an ACEI or ARB, and a BB
Willing to understand and comply with study procedures and provide written informed consent.
Hospitalization within 4 weeks of baseline visit
History or presence of gastrointestinal conditions such as severe constipation or gastrointestinal tract strictures
Current or anticipated dialysis during study
In the investigator's judgment, any cardiovascular, renal, hepatic, endocrine, gastrointestinal, neurological, or other disease or condition that makes the subject's study participation unsafe